MorphoSys, a company whose research has yielded programs placed with big pharmaceutical companies and upstart biotechs, is stopping all preclinical work to focus on cancer, particularly a late-stage drug candidate it acquired in a…
Continue Reading
Multinational pharmaceutical and biotech company Pfizer and AI-powered data company Tempus announced a multi-year strategic alliance to utilize AI and machine learning to inform drug discovery and development in oncology. Pfizer will leverage Tempus’ library…
Continue Reading
Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of its second startup, DenovAI.DenovAI will develop an AI-enabled computational biophysics platform that can discover potential antibodies…
Continue Reading
Researchers at the Harvard Wyss Institute are collaborating with a biotechnology company called Gameto to develop human ovarian organoids that will allow the study of reproductive and other health issues using tissues that closely…
Continue Reading
Aptinyx’s approach of treating neurological disorders by targeting a key receptor in the brain has fallen short again, this time in Parkinson’s disease. With its third clinical trial failure in less than a year,…
Continue Reading
Mark Diamond, Managing Director and CEO at Antisense Therapeutics Limited joins eHealth Radio and the Health News Channel. Antisense is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet…
Continue Reading
Moderna’s ambitions in messenger RNA technology include therapies that do their editing work inside the patient. To that end, the biotech company is starting an R&D collaboration with a division of ElevateBio that brings…
Continue Reading
Clotting disorders can be treated by infusing patients with clotting proteins they lack, or with drugs that replace the function of these proteins. Gene therapies may soon become another option. Hemophilia A and B…
Continue Reading
Talaris Therapeutics aimed to transform solid organ transplants with a cell therapy that replaces anti-rejection drugs patients need for the rest of their lives. But after clinical trial setbacks, the biotech has decided to end two kidney transplant studies. Although a separate test of its experimental therapy is continuing in a rare autoimmune condition, Talaris has commenced a restructuring plan that it said could culminate in a merger or sale of the company.
The restructuring announced Thursday will lead to the layoff of about one-third of Talaris’s staff. As of the end of the third quarter of 2022, the Louisville, Kentucky-based biotech…
Indian biotech company Mylab Discovery Solutions is integrating Qure.ai’s AI technology into its upcoming x-ray device for screening tuberculosis.According to a press statement, MyBeam is a compact, lightweight device equipped with high-frequency technology for detecting TB. It will be powered by Qure.ai’s deep-learning software qXR to analyse chest x-ray images and identify TB within a minute.
WHY IT MATTERS
India is one of the biggest contributors to global TB cases, accounting for 26% of the total global count and 34% of all TB deaths.
By leveraging technological innovation, both Mylab and Qure.ai aim to support the Indian government’s goal of eliminating TB by 2025. Their integrated…
